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Ischaemic heart disease (IHD) in pregnancy, particularly myocardial infarction (MI), is a rare yet potentially fatal
condition for the mother and the foetus. With delays in the age of conception, the changes in some social habits among
females including cigarette and shisha smoking in addition to an increased prevalence of diabetes mellitus, IHD may
represent a real hazard among pregnant women in the near future. The difficulty in the diagnosis emerges from the
similarity of the signs and symptoms of ischaemia and infarct to some of the physiological adaptations that occur in a
normal pregnancy. The physiological changes that are normal in pregnancy may aggravate pre-existing disease and may
unmask some underlying unrecognized coronary vascular changes; therefore, the diagnosis requires a high index of
suspicion and careful assessment of the underlying risk factors. The management of IHD always requires a
multidisciplinary team approach. The management of each patient should be individualized according to the clinical
condition, the risk factors, and the availability of the necessary support. Pregnancy after MI may be an acceptable and
reasonably safe option provided the cited criteria are met. A systematic PubMed search was performed to identify all
published data including cases reports, small series and systematic reviews in the existing literature. These
publications were comprised of both retrospective and cross sectional population studies to maximize the number of
cases considered in order to reach conclusions and make recommendations based on the best available evidence
considering the rare occurrence of this event. The epidemiology, diagnosis, medical and surgical treatment, and
prognosis of IHD in pregnancy are the subjects of the present review.
 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Women in the reproductive age group areconsidered low risk for the development
of coronary artery disease and myocardial
infarction (MI). Pregnancy increases the risk of
MI by 3–4 times [21]. In the discrete interval of
pregnancy the incidence is even lower, and has
been estimated to occur at a frequency of
approximately 3–10 per 100,000 deliveries
[9,41,1,16,47,12]. The incidence of coronary artery
ischaemic disease and MI is increasing among
pregnant women, most probably as a result of
the increased incidence of smoking among
females [16,42,9]. While MI is rare in pregnancy,
when it occurs it is associated with a dispropor-
tionately high maternal mortality rate which was
reported to be 5–37% [9]. The mortality rate in 68
cases was 35% [16]. Among these cases only 13%
of the patients were known to have had coronary
artery disease prior to the pregnancy, and the
remaining cases occurred among patients in
whom there was no clinical suspicion of coronary
artery disease. Two-thirds of the women suffered
their infarction in the third trimester; the mortality
for these women was 45% as compared to 23% in
patients who had an infarct in the first or second
trimester. Therefore treatment needs to be prompt
and urgent due to the high mortality rate and the
grave outcome associated with some cases.Physiological changes in pregnancy
Pregnancy is associated with dramatic hemody-
namic changes which may predispose patients
with unrecognized coronary artery disease to de-
velop symptoms of infarction. These changes in-
clude increase in the intravascular volume by
50% reaching a zenith by early to mid-trimester;the increased plasma volume adds further stress
and may lead to worsening ischaemia. The
increased plasma volume is associated with an
increase of 30–50% in stroke volume.
Throughout pregnancy, the cardiac output in-
creases by 40–60%. In the first trimester cardiac
output increases by approximately 25%, by 50%
in the second trimester and by up to 80% in the
third trimester [50]. In labour there is a further in-
crease in cardiac output; up to 500 ml is forced into
the intravascular space. At delivery there may be a
further auto transfusion followed by a drop in
cardiac output associated with post-partum
bleeding and with the release of vena caval
pressure.
Pregnancy is a relative hypercoagulable state
which increases with advancing gestation and
reaches an acme at or around delivery and in
the early post-partum period.Classification of IHD
In general IHD are classified into angina pecto-
ris (transient myocardial ischaemia) and MI (fixed
myocardial ischaemia/necrosis).Angina pectoris
In its various manifestations angina pectoris is
relatively rare in pregnancy with only a few
reported cases. Most women who have MI in
pregnancy present with sudden infarction that is
not preceded by angina pectoris. Despite the rar-
ity of angina pectoris in pregnancy, patients with
angina pectoris in pregnancy should be consid-
ered at high risk of developing subsequent MI
and should be managed accordingly.
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Myocardial infarction presents in pregnancy
with a variety of symptoms. Classically the patient
will complain of central chest pain, usually severe
in nature, radiating to the jaw and left arm. The
pain may be associated with faintness or even
collapse, the patient will be extremely anxious,
sweating and may have some nausea and
vomiting.Epidemiology of myocardial infarction in
pregnancy
The first case of MI in pregnancy was reported
by Katz [24]. Between 1922 and 1985, 70 cases of
MI in pregnancy were reported [16] with an aver-
age of 1.1 case reports per year. Between 1986 and
1989 an additional 38 cases were reported bringing
the total number of cases to 108 [42] and giving an
incidence of approximately 7.6 cases per year.
Between 1990 and 1994 an additional 32 cases have
been reported with an average of eight case re-
ports per year. From 1995 until 2005, 103 cases
were reported with an average of 9.4 cases per
year [26].
In total until 2005 there have been 251 cases of
MI reported in pregnancy (Table 1). It is unclear
from the literature whether the incidence of MI
is increasing or more of these cases are being re-
ported. In recent years the changes in the obstet-
rics practice may have altered or even increased
the incidence of MI. Thus, for example, illicit drug
use (cocaine), the use of tocolytics (Ritodrine),
prostaglandins (PGE2) and the increase of multi-
ple pregnancies in the population as a conse-
quence of assisted reproductive technology may
all have contributed to the apparent increased
incidence of MI. It is important to realize that
information related to ischaemic heart disease in
pregnancy is derived from case reports and small
series, therefore, is subject to considerable report-
ing bias.Maternal mortality
The maternal mortality related to MI in
pregnancy is a significant and devastating event;
in the early reports the mortality rate was as high
as 50% in the peripartum period [16]. Reports in
the last decade have revealed a reduction in the
maternal mortality rate probably related to early
detection and the advance in the medical care,
particularly invasive cardiology, intensive care
units, anaesthesia and high-risk obstetric practice.
The maternal mortality reported by Roth andElkayam [41] had declined from 21% in their
1996 review to 11% in their second review of all
MI cases reported in the last decade [42]. Others
had reported a lower mortality rate including
7.3% [26] and 5.1% [21]. The risk of death from
MI increases as pregnancy advances: mortality
rate in the first and second trimester is approxi-
mately 25%, in the third trimester 40%, and if
the infarction occurs in the peripartum period,
the mortality rate increases to 50% [16]. Data from
the last decade showed that the mortality rate
almost doubled if the infarction occured in the
peripartum period compared to antepartum and
post-partum period [42,26].Foetal loss
The foetal loss rate is primarily the result of the
maternal outcome. Overall the foetal loss rate with
MI in pregnancy was 37% in the early reports [16]
which decreased to 9% in more recent reviews
[42].Predisposing factors
Risk factors that predispose to MI are smoking,
maternal age, familial hyperlipidaemia, hyperten-
sion and diabetes mellitus. Pregnancy is known to
be associated with an increased probability of
developing hypertension (preeclampsia, eclampsia)
or for the worsening of pre-existing essential or
secondary hypertension. In one-third of the cases
of MI in pregnancy that have been reported, there
was a history of elevated blood pressure [16,34,15].
In a recent review of MI associated with preg-
nancy in the last decade Roth and Elkayam [42] re-
ported that among the 103 studied cases 45% of
the patients were smokers, 24% had hyperlipidemia,
22% had family history of MI, 15% had hypertension
and 11% had diabetes mellitus. They also reported
that 72% of the patients were older than 30 years
and 38% were older than 35 years. James [21]
added to the list thrombophilia, transfusion and
post-partum infection as significant risk factors.Myocardial infarction aetiological
classification
Based on autopsy findings, MI in pregnancy
may be due to a variety of causes. Arterial sclerotic
vascular disease is the most common pathological
finding in pregnant women who have died from
MI [12,23,42,25].
Embolic complications secondary to cardiac
arrhythmia are an unusual but recognized cause
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spontaneous, familial, or ergot-induced is a rare
but recognized cause of MI in pregnancy
[4,13,18]. Aneurysm, haematoma, and/or sponta-
neous dissection of the coronary artery vessels
have been reported [32,45,51]. Collagen vascular
disease [38,40] and congenital malformations such
as aortic valvular stenosis or anomalous origin in
the coronary arteries vessels are among the rare
causes of MI in pregnancy [36]. Other rarer causes
include cocaine abuse [29], pheochromocytoma
[22], sickle cell anaemia [49] and Kawasaki disease
[35]. With the development and introduction of
some pharmacological agents in obstetrical prac-
tice, some reported cases of MI were linked to
those agents including prostaglandin E [48] and
clomiphene citrate (CC) prescribed for ovulation
induction [8].
Twenty-nine percent of the 123 cases reviewed
by Roth and Elkayam [41] by defining the coro-
nary artery anatomy were found to have normal
coronary arteries and it was hypothesized that
the cause of the infarction may have occurred
because of transient coronary arteries spasm.The diagnosis of myocardial infarction in
pregnancy
The diagnosis of MI in pregnancy may be difficult
and is challenging for the following reasons: the
disease is rare in pregnancy and therefore is rarely
considered in a young apparently healthy
population and the physiological adaptations of
pregnancy may mimic the signs and symptoms of
cardiac disease in non-pregnant patients. Such
symptoms and signs include dyspnoea, palpitation,
decreased exercise tolerance, nausea and heart burn,
epigastric or chest pain (gastro-oesophageal reflux),
peripheral oedema distended neck veins, lateral dis-
placement of the cardiac apex, and the presence of a
third heart sound and ejection systolic murmur. In
the non-pregnant patient these symptoms and signs
are commonly observed in patients with IHD with
associated myocardial damage. In pregnant patients
these findings may be normal. Therefore caution
should be taken to avoid confusing the epigastric
and chest pain of gastro-oesophageal reflux with
angina pectoris. The occurrence of sweating and
faintness with chest pain is not a feature of
gastro-oesophageal reflux and strongly suggests
IHD.
Physiological EKG changes such as left axis devi-
ation, T-wave inversion and non-specific ST
changes have been reported in as high as 37% in
women having elective caesarean section [31,37].In the non-pregnant patient these findings are of
the patient experiencing coronary artery disease
or infarction. The interpretation of the EKG in the
pregnant women will depend on the index of sus-
picion and on the severity of patient’s complaint.Pregnancy-associated plasma protein-A
Pregnancy-associated plasma protein-A
(PAPP-A) is one of the circulating proteins in the
maternal plasma and is present in unstable
plaques. Elevated levels of PAPP-A in pregnancy
may reflect instability of atherosclerotic plaques.
PAPP-A is a new candidate marker of unstable an-
gina and acute MI and may have diagnostic value
in unstable angina or acute MI during pregnancy
[2]. The early reports on the utilization of PAPP-
A in coronary artery disease in pregnancy was fur-
ther supported by several investigations. You [54]
measured the plasma level of PAPP-A in 70 pa-
tients with acute coronary syndrome, comprised
of 18 with unstable angina, 37 with acute MI and
15 with stable angina; Levels of PAPP-A were sig-
nificantly higher in the unstable angina and acute
MI groups than in the stable angina and control
groups. Furthermore an elevation of PAPP-A level
in patients with negative troponin testing was de-
tected and the researchers concluded that PAPP-A
seems to be associated with inflammation and
might be used to detect plaque instability and
rupture before an increase in cardiac troponin is
detectable.
Investigating whether pregnancy-associated
plasma protein-A (PAPP-A) is a prognostic
marker in patients admitted with high-risk acute
coronary syndrome. Iversen [19] examined two
populations of patients admitted with a high-risk
of non-ST-segment elevation acute coronary
syndrome (NSTE-ACS), (123 patients) and ST-seg-
ment elevation myocardial infarction (STEMI) (314
patients). These patients were evaluated with seri-
al measurements of PAPP-A. The incidence of
mortality and nonfatal MI was reported for 2.66
to 3.47 years and it was concluded that PAPP-
A seems to be valuable in predicting the outcomes
of patients admitted with high-risk NSTE-ACS or
STEMI.
Addressing the prognostic value of serum
PAPP-A in unselected stable CAD patients,
Iversen [20] followed 4243 patients prospectively
and reported the causes of mortality and con-
cluded that in patients with stable CAD elevated
serum PAPP-A seems promising as aid in identi-
fying patients at high risk for death.
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The typical presenting symptom of MI is excru-
ciating retrosternal chest pain that radiates to the
left shoulder. The critical point to differentiate
the pain related to MI from other causes of chest
pain related to pregnancy is the intensity of the
pain and diaphoresis (sweating) which is usually
associated with myocardial ischaemia/infarction.
In the patient with acute MI the physical examina-
tion is non-revealing. Occasionally cardiac mur-
murs may be heard but this is not diagnostic
and generally not useful. The observation of pul-
monary oedema and heart failure are hallmark
features of severe MI and portend a worse
prognosis.Laboratory investigation
The troponin I level in serum appears to be the
marker of choice of myocardial injury in the
pregnant patient because levels are not altered
by normal pregnancy and delivery or influenced
by obstetric anaesthesia [43].
Cardiac enzymes are useful in the diagnosis of
MI. An elevated keratinise kinas CK-MB fraction
is a characteristic feature of MI. It is important to
note that CK-MB may be elevated in labour
[7,43]. A rising level of CK-MB (>5% of total CK)
in the presence of signs and symptoms of MI is
diagnostic. Elevated LDH is less reliable in the
diagnosis of MI and needs to be interpreted with-
in the overall enzyme profile. The EKG changes of
MI or ischaemia and infarction are well described.
Sustained T-wave inversion, ST-segment depres-
sion, and q-wave formation are diagnostic
features of MI.Diagnostic imaging
Two-dimensional echocardiography and deter-
mination of ventricular ejection fraction are useful
in assessing the severity of myocardial damage
but are of limited value in making a diagnosis.
Radio-nucleotide imaging is a useful technique
to assess coronary artery patency. This technique
requires the use of radioactive thallium or
Sestamibi and as such presents a theoretical risk
of radiation exposure to the foetus. The estimated
total dose of radiation exposure with thallium
nucleotide heart scan is estimated to be less than
1 rad [6]. In symptomatic patients or in patients
in whom coronary artery disease is strongly sus-
pected this minor foetal radiation exposure is an
acceptable risk.Invasive testing
Cardiac catheterization was reported in 386 pa-
tients by James [21]; however, no information
was provided regarding the outcome of these pro-
cedures. In the review by Roth and Elkayam [42]
cardiac catheterization was performed in 92
(89%) of the 103 patients reviewed with equal dis-
tribution among patients presented antepartum,
peripartum, or post-partum. The procedure re-
sulted in fatal coronary dissection in one patient,
and coronary dissection leading to bypass surgery
in another. Since this procedure has been associ-
ated with maternal death coronary artery angiog-
raphy and catheterization is an option that should
be reserved for selected patients only [4].Complications
The complications that occur with MI do not dif-
fer between pregnant and non-pregnant patients.
A summary of the common complications is given
in Table 2.Management
The management of ischaemic heart disease in
pregnancy should be a multidisciplinary team ap-
proach, including an obstetrician, cardiologist,
anaesthesiologist, dietician and a social worker.
This team should work together to advise the
patient on how to eliminate and avoid risk factors
for subsequent ischaemia and infarction, to recog-
nize the progression of ischaemia to infarction, to
institute the appropriate monitoring systems and
to prepare the patient for the potential complica-
tions of the condition. In early pregnancy the issue
of abortion for the treatment of the patient with
IHD is controversial ([46,30]. The evidence that
pregnancy termination diminishes the risk in the
patient with myocardial ischaemic infarction is
unclear. However for the patient with evidence
of worsening ventricular failure pregnancy termi-
nation may be a preferable option.
General measures
In the symptomatic patient bedrest to reduce
oxygen demand may be beneficial. Oxygen sup-
plementation should be initiated in patients dur-
ing acute attacks. In patients with infarction pain
control is an important aspect of their care. Anal-
gesia should be given intravenously, and should
be adequate to reduce or eliminate the pain. The
benefit of pain reduction is a decrease in anxiety
and stress. Morphine (risk category C) is the agent
of choice. In addition to its powerful analgesic
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increasing venous pooling. Morphine should be
administered intravenously since this route
produces immediate effect and avoids release of
muscle enzymes at the injection site which may
lead to confusion in the interpretation of cardiac
enzyme profiles.
Decreasing anxiety by providing emotional and
psychological support to the patient may reduce
the incidence of MI or prevent the extension of
the existing one.
In the patient with acute MI in late pregnancy
delivery should be delayed. Ideally the patient with
an acute infarct should remain undelivered for at
least two weeks after the onset of the infarct.
Prolonging the interval between infarct and
delivery has been shown to reduce the mortality
rate by at least 15%, from 50% to 35% or less
[12,23]. This is an important clinical point because
in some instances the occurrence of infarct creates
an anxiety among the obstetric team to deliver the
patient.
The ideal delivery position is the lateral
recumbent position. This position will avoid vena
caval compression and its subsequent reduction
in venous return, stabilization of venous return
may be reflected in improved cardiac contractility,
sustained coronary blood flow and diminished
myocardial oxygen demand.
The patient in labour with acute MI should be
managed in the Coronary Intensive Care Unit.
Since these patients are at risk for acute extension
of the myocardial infarct and acute lethal dys-
rhythmias, their care should be in an area where
immediate and appropriate response is available.
Since in most instances the foetus is unaffected
by the maternal MI, the focus should be to the
mother and less so to the foetus.
In patients with MI continuing pregnancy mon-
itoring in hospital is recommended. Careful and
frequent assessment for signs and symptoms of
heart failure and/or ventricular dysrhythmias
should be part of the post-infarction care. The role
of prophylactic antiarrhythmic drugs is controver-
sial. In general, in the patient with uncomplicated
MI who is not exhibiting serious dysrhythmia
there is no role for prophylaxis. In patients who
have transient dysrhythmias or sustained dys-
rhythmias, intravenous prophylaxis is indicated.
Antiarrhythmic treatment should be initiated by
the cardiologist and in consultation with the
obstetrician. Intravenous Lidocaine (risk category
B) is usually the drug of choice for controlling
acute dysrhythmias in the setting of an MI.The occurrence of heart failure, manifested by
worsening peripheral and pulmonary oedema is
a medical emergency in the patient with acute
MI. The use of furosemide to reduce intravascular
volume is recommended. Patients with MI are
predisposed to developing thromboembolic dis-
ease. This risk is probably increased in pregnancy
because of the hypercoagulable state known to ex-
ist in pregnancy. Accordingly, prophylactic hepa-
rin should be initiated. The usual dose is 5000–
10,000 SC bid for unfractionated Heparin, low
molecular weight Heparin such as Enoxaparin
40 mg bid (risk category C) can be used despite
the fact it has a longer half life with theoretical risk
of bleeding if the patient started labouring within
few hours of the administration. In patients with a
suspected or proven intramural thrombus full
heparinization is mandatory.Specific measures
Specific measures for the treatment of patients
with acute MI include both surgical and medical
interventions. Nitro-glycerine (risk category B) gi-
ven either orally, sublingually, intravenously or by
dermal patch, can be used in the treatment of the
patient with acute MI. In the presence of nitro-
glycerine the coronary vessels are dilated leading
to improved myocardial perfusion. Nitro-glycer-
ine has no known teratogenic effects; however,
careful adjustment of the dose is needed to avoid
maternal hypotension leading to foetal distress.
The use of nitro-glycerine has not been shown to
reduce infarct size or mortality in the thrombolytic
era. Special care is needed in patients with inferior
MI and right ventricular involvement with the
use of nitro-glycerine as it can cause severe
hypotension.
The use of beta blockers and calcium channel
blockers (risk category C) in the treatment of acute
MI is controversial [15]. Despite published reports
on their safety in pregnancy [5,11], the decision to
use these medications should rest with the cardi-
ologist managing the case, in consultation with
the obstetrician.
Thrombolytic agents are used as acute therapy
for occlusion of the coronary vessels and preven-
tion or limitation of MI. Tissue plasminogen acti-
vators (t-PA) such as tenecteplase (TNKase) and
Reteplase are the agents of choice. The complica-
tions of these agents include bleeding, premature
labour and incoordinate uterine contractions; the
risk/benefit ratio of thrombolytic agents is contro-
versial [14,27,28,33,39,44,53]. The decision to utilize
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between the cardiologist and the obstetrician.
In cases of MI that do not respond to thrombo-
lytic agents, rescue PCI (percutaneous coronary
intervention) of the infarct related artery can be
performed with acceptable results.
Percutaneous transluminal coronary angioplasty
or percutaneous coronary intervention
Percutaneous coronary intervention (PCI) for
the treatment of coronary artery occlusive disease
is a well established treatment modality in pa-
tients with angina pectoris and acute MI. James
[21] reported PCI in 135 pregnant patients with
stent placement in 127 of them. No information
was provided on the timing of these procedures
or their outcome. In a review by Roth and Elka-
yam [42] coronary angiography was performed
in 92 of 103 patients included in their review; 49
of these procedures were done antepartum and
43 post-partum. PCI was performed in 38 of 92
(41%) subjects (23 antepartum, six peripartum,
and nine post-partum) with stent placement in
55% of these patients. Duration of pregnancy in
23 patients who underwent the procedure in the
antepartum period (mostly in the third trimester)
ranged from 6 to 38 weeks. All reported stenting
during the acute phase of MI during pregnancy
were performed with bare metal stents; the safety
of drug-eluting stents in pregnant woman is
therefore still unknown. Because drug-eluting
stents require prolonged antiplatelet therapy and
the incidence of caesarean section deliveries in
patients with heart disease is relatively high, the
use of drug-eluting stent during pregnancy may
be problematic and should be avoided if possible.
Coronary artery bypass in pregnancy has been
associated with a maternal mortality rate of 1–2%
and a foetal loss rate of approximately 33%; the
mortality figure with coronary by-pass in the
pregnant population does not differ from that
observed in the non-pregnant population in one
limited report [3]; however, the limited available
information precludes reaching definite conclu-
sions regarding the safety of coronary artery
bypass graft surgery during pregnancy.Labour and delivery
Timing of delivery
The occurrence of an MI in pregnancy is an indi-
cation to delay delivery after the infarct. The
maternal mortality is inversely related to the inter-
val between the infarct and delivery. Every effort
should be taken to stabilize the patient after theinfarct and defer delivery. It is assumed that dur-
ing the period of infarct the maternal cardiovascu-
lar system is unstable, and the superimposition of
the stresses of labour can lead to acute deteriora-
tion. Within approximately 5–7 days after acute
myocardial infarct a degree of stability returns to
the maternal ventricular function and the risk of
added stress of labour diminish.
Analgesia in labour
Epidural analgesia is the method of choice in the
patient with a previous MI. The advantages of
epidural analgesia are: marked decrease in the
pain, stress, and anxiety, decrease in the afterload
reduces the amount of cardiac work required.
Preload reduction is a recognized potential dis-
advantage of epidural anaesthesia. This complica-
tion can be prevented by ensuring that the patient
is adequately hydrated at the time of induction of
the epidural. Vasopressure agents are contraindi-
cated in the treatment of epidural induced hypo-
tension in the patient with a previous MI.
Mode of delivery
In patients with an MI vaginal delivery is the
method of choice. Caesarean section should be re-
served only for those patients with obstetrical
indications and should be approached very
cautiously. The reported maternal mortality with
vaginal birth after MI is 14% whereas the mortal-
ity in patients delivered by caesarean section is
23% [12,23]. The advantages of vaginal birth are
the elimination of the surgical stress, the lack of
a general anaesthetic, lower incidence of post-par-
tum infection, and diminished blood loss. Patients
delivered vaginally are more likely to ambulate
early, thereby reducing the risk of thromboembo-
lic disease. There is usually minimal need for
analgesics after vaginal delivery. The disadvan-
tages of vaginal delivery are the prolongation of
the delivery process and the unpredictable mode
and time of delivery.
The advantages to caesarean section are that
delivery can take place under controlled circum-
stances, with the personnel and equipment re-
quired for care of the mother and the foetus
immediately available. Caesarean section is associ-
ated with shorter duration of the hemodynamic
changes associated with the delivery process. The
disadvantages of caesarean section include in-
creased blood loss which may be associated with
hypotension, which in turn may either precipitate
a second infarct episode or lead to extension of
the existing infarct. Caesarean section is also
associated with an increased risk of infection,
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associated with a surgical procedure and the heal-
ing process.
In the patient with acute heart failure as a conse-
quence of MI, caesarean section is the method of
choice for delivery [17].
In patients in whom the decision has been made
to attempt a vaginal delivery it is usually recom-
mended that the second stage be foreshortened
by the use of outlet forceps or vacuum extractor
[44].
Management of the third stage of labour
In the patient with an uncomplicated vaginal
delivery, no active intervention is required in the
management of the third stage. In patients who have
experienced complicated third stage of labour
aggressive treatment is always indicated. In particu-
lar, patients with post-partum haemorrhage should
be treated early. Oxytocin is the drug of choice for
controlling post-partum haemorrhage in a patient
with previous MI. Ergot compounds are contraindi-
cated. The use and safety of prostaglandin F2a in pa-
tients with MI has not been demonstrated to date.Indication for invasive monitoring
The use of Swan-Ganz catheters and arterial
lines to monitor blood pressure, central venous
pressure, pulmonary artery and pulmonary
wedge pressure is indicated only in patients in
whom there is evidence of or a strong suspicion
of heart failure.Preconception counselling and
recommendations
A critical question raised by the patient is, ‘‘What
are the risks of recurrence of MI and death with a
subsequent pregnancy?’’ Frenkel [10] reviewed
the literature and reported 20 cases of pregnancy
following MI. In this report they added an addi-
tional four cases from their own experience.
No maternal deaths occurred in subsequent
pregnancies. Two foetal losses were reported. They
suggested that subsequent pregnancy in a patient
with an MI is associated with a small but definitely
increased risk of perinatal loss. Vinatier [52]
reported 30 cases in the literature and added one
case of their own where they concluded that
pregnancy after MI is possible provided that
certain precautions are taken including a
pre-pregnancy cardiac examination to evaluate
the cardiac function and to screen for aetiology for
coronary disease. While these series are small, theresults are encouraging. Patients should be advised
that there is some increased probability of in-
creased MI, but in the majority of instances the
pregnancy proceeds without complication. It may
also be added to ensure an optimal outcome in
those cases that the patient should be symptom-
free without medication, the period between infarct
and pregnancy should be more than one year and
the patient should have had a recent negative
coronary angiogram and have no residual left
ventricular dysfunction on echocardiography.Conflict of Interest
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